New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
Executive Summary
AbbVie boosted its revenue guidance, increasing its longer-term Humira forecast from $18bn in 2020 to $21bn, raising the bar for drugs that will make up for revenue lost when biosimilar competition arrives in five years.
You may also be interested in...
Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions
Analysts already were skeptical about AbbVie's $5bn peak earnings projections for the ADC, but now some wonder if so-so data in third-line small cell lung cancer threaten Rova-T's viability for approval.
Get Ready For The Return Of The Mega-Merger, Leerink Says
Following tax reform, analysts expect imminent biopharma mega-mergers, with Pfizer, Merck and Roche looking to buy, AstraZeneca, Bristol and Vertex looming as take-out candidates, and Amgen as either a buyer or a target.
AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids
AbbVie announced positive data from the first of two pivotal Phase III studies testing the GnRH receptor antagonist, but Allergan and Myovant are among the companies also looking to bring new drugs to market.